Skip to main content
PMC home page
Frontiers in Pediatrics logoLink to Frontiers in Pediatrics
. 2022 Nov 21;10:980024. doi: 10.3389/fped.2022.980024

High-flow nasal cannula versus continuous positive airway pressure in primary respiratory support for preterm infants: A systematic review and meta-analysis

Keren Luo 1, Yi Huang 1, Tao Xiong 1, Jun Tang 1,*
PMCID: PMC9720183  PMID: 36479290

Abstract

Respiratory support is crucial for the survival of preterm infants, and High-flow Nasal Cannula Oxygen Therapy (HFNC) and Continuous Positive Airway Pressure (CPAP) are commonly used for neonatal respiratory support. This meta-analysis aimed to compare the effects of HFNC and CPAP in primary respiratory support for preterm infants, to provide evidence-based support for clinical practice. PubMed, Embase, Cochrane Library, ClinicalTrials.gov, CNKI, VIP, WANFANG and SinoMed were searched for eligible studies. The primary outcomes included the incidence of treatment failure and the application of mechanical ventilation. A total of 27 eligible studies with 3,351 participants were included. There was no significant difference in the incidence of respiratory support failure [RR = 1.17, 95%CI (0.88–1.56)] and the application of mechanical ventilation [RR = 1.00, 95%CI (0.84–1.19)] between HFNC group and CPAP group. HFNC resulted in lower rate of air leaks [RR = 0.65, 95%CI (0.46–0.92)], nasal trauma [RR = 0.36, 95%CI (0.29–0.45)] and abdominal distension [RR = 0.39, 95%CI (0.27–0.58)], and later time of mechanical ventilation initiating [SMD = 0.60, 95%CI (0.21–0.99)], less duration of oxygen therapy [SMD = −0.35, 95%CI (−0.68 to −0.02)] and earlier enteral feeding [SMD = −0.54, 95%CI (−0.95 to −0.13)]. Alternative non-invasive respiratory support after initial treatment failure resulted in no difference in the application of mechanical ventilation between the two groups [RR = 0.99, 95%CI (0.52–1.88)]. HFNC might be more effective and safer in primary respiratory support for preterm infants. Using CPAP as a remedy for the treatment failure of HFNC could not avoid intubation. For premature infants with the gestational age <28 weeks, HFNC as primary respiratory support still needs to be further elucidated.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022313479, identifier: CRD42022313479.

Keywords: high-flow nasal cannula oxygen therapy, continuous positive airway pressure, neonatal respiratory support, meta-analysis, respiratory failure

Introduction

Respiratory failure is one of the primary causes of mortality in preterm infants in Neonatal Intensive Care Units (NICU), making it mostly important to perform respiratory support timely for the newborns (1). Continuous Positive Airway Pressure (CPAP) is one of the earliest applied and conventional non-invasive respiratory support methods (2), which could reduce the risk of respiratory complications also decreasing mortality and improving neurological prognosis in preterm infants (3, 4). However, CPAP has high skill requirements for nurses as the improper use would lead to adverse outcomes including nasal mucosal injury or necrosis, nasal granuloma, nasal vestibular stenosis, and nasal septum deformation or deletion in infants, and the special caps that needs to be worn for fixation to ensure ventilation effect would add discomfort for infants (2, 5, 6). High-flow Nasal Cannula Oxygen Therapy (HFNC), also known as Heated Humidified High Flow Nasal Cannula (HHHFNC), is a newly emerged non-invasive respiratory support technology and has been increasingly applied in NICU as an alternative to CPAP (1, 7–13). Compared with CPAP, HFNC has several merits in promoting alveolar dilation (14–18), improving gas exchange (14, 19), protecting airway mucosa (20), and reducing respiratory work (19).

Neonatal respiratory distress syndrome (NRDS) is a common respiratory complication in premature infants. Surfactant and non-invasive ventilation are the standard treatment for NRDS. Treatment failure is defined as the need for other forms of respiratory support due to the presence of respiratory acidosis, hypoxemia, severe apnea, etc. (21, 22). In recent years, multiple studies, including randomized controlled trials (RCTs) and systematic reviews that compared the effects of HFNC and CPAP, have yielded conflicting results. Some studies (23–29) suggested that HFNC was as effective as CPAP, while the others (30–34) found that the failure rate for HFNC was higher than that for CPAP.

However, published systematic reviews did not thoroughly summarize the current evidence due to several reasons such as language limitation, and the outcomes included were too limited to fully reflect the therapeutic effect of HFNC/CPAP to be the primary respiratory support approach for preterm infants with NRDS (26, 27, 29, 32–34). On the other hand, there have been some new studies published in recent years. We performed this systematic review and meta-analysis, based on a more comprehensive literature search, to compare the effects of HFNC and CPAP in respiratory support for preterm infants, so as to provide evidence-based medical support for clinical practice.

Methods

Study registration

This systematic review and meta-analysis was conducted following the PRISMA statement (35) and has been registered on PROSPERO (Registration No. CRD42022313479) (36).

Inclusion criteria and exclusion criteria

Randomized controlled trials (RCTs) comparing the effects of CPAP and HFNC in primary respiratory support for preterm infants (Defined as infants with gestational age <37 weeks) were included. Studies with non-RCT-design, incomplete data, or data unavailable were excluded.

Outcome measures

Primary outcomes included the incidence of treatment failure and application of mechanical ventilation after non-invasive respiratory support. Outcomes of safety included air leaks, nasal trauma and abdominal distension.

Secondary outcomes included age of respiratory failure onset, duration of mechanical ventilation/non-invasive respiratory support/oxygen therapy, time of mechanical ventilation initiating, time of enteral feeding, exclusive breastfeeding, death, length of hospital stay, and report of adverse events such as hypercapnia, apnea, pulmonary hemorrhage, pneumonia, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia, retinopathy of prematurity (ROP), patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC), sepsis, and requirement for other treatment.

Literature search

PubMed, Embase, Cochrane Library, ClinicalTrials.gov, CNKI, VIP, WANFANG and SinoMed were searched for relevant articles from inception to February 26th, 2022, with no language restriction. Literature search was conducted by two reviewers independently (Luo and Tang). Detailed search strategy is provided in Appendix 1.

Literature screening and quality assessment

All the retrieved articles were screened through browsing titles and abstracts to exclude ineligible studies. Afterwards, the full-text of remained articles were read to identify studies that should be included.

The Cochrane risk of bias assessment tool was used for assess the quality of included study, which includes the following 7 items: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting; (7) other bias. Each item could be graded as low risk, high risk, and unclear bias.

Literature screening and quality assessment were performed by two reviewers independently (Luo and Tang). Any disagreements were consulted and settled by a third reviewer (Huang and Xiong).

Data extraction

Data extraction was processed by two reviewers independently (Luo and Tang) using a pre-designed form. Any controversies were resolved through discussion or by a third reviewer.

Data synthesis and analysis

Revman was used to conduct the data analysis, and STATA was used to assess the publication bias if needed (No. of included studies >10). Standard mean difference (SMD) with the 95% Confidence interval (95%CI) were pooled for continuous data, and risk ratio (RR) with the 95%CI for dichotomous data. A p value less than 0.05 with the 95%CI not included the null indicated statistical significance. Heterogeneity was conducted using I² statistics. Random effect model was applied as pooled statistics if I² > 50%, otherwise fixed effect model would be applied. Sensitivity analysis was conducted by removing studies with potential heterogeneity.

Results

Characteristics of included studies

There was 723 related articles identified. After reading the titles, abstracts and full texts, a total of 27 eligible studies with 3,351 participants (1,664 in HFNC group and 1,687 the CPAP group) were included (23–25, 28, 30, 31, 37–57). The flow diagram for study selection is shown in Figure 1. Among the included studies, 2 included both premature infants and term infants (28, 43), and only data of premature infants was extracted, 2 studies did not specify whether the included preterm infants had NRDS (25, 50), and 3 studies included preterm infants with early respiratory distress, or an intention to respiratory support (44, 48, 57). The participants reported in the other studies were all preterm infants with NRDS. The basic characteristics of included studies is shown in Table 1.

Figure 1.

Figure 1

Open in a new tab

Flow chart.

Table 1.

Characteristics of included studies.

Author Year Region Study design Gestational age Comparison
Armanian 2019 Iran RCT <37 weeks HHHFNC (2.5–3 L/min, n = 35); nCPAP (5–6 cm H2O, n = 37)
Chen 2015 China RCT <37 weeks HHHFNC (2–8 L/min, n = 34); nCPAP (5–7 cm H2O, n = 32)
Ciuffini 2014 Italy RCT 29–36 weeks HHHFNC (4–6 L/min, n = 85); nCPAP (4–6 cm H2O, n = 92)
Demirel 2019 Turkey RCT <32 weeks HHHFNC (6–8 L/min, n = 53); nCPAP (6–7 cm H2O, n = 54)
Farhat 2018 Iran RCT 28–34 weeks HHHFNC (2–5 L/min, n = 54); nCPAP (6–8 cm H2O, n = 53)
Feng 2016 China RCT <37 weeks HHHFNC (n = 62); nCPAP (n = 68) “detailed parameters” was not provided.
Kadivar 2016 Iran RCT 28–34 weeks HHHFNC (2–4 L/min, n = 27); nCPAP (5–8 cm H2O, n = 27)
Lavizzari 2016 Italy RCT 29–36weeks HHHHFNC (4–6 L/min, n = 158); nCPAP (4–6 cm H2O, n = 158)
Li 2014 China RCT <37 weeks HHHFNC (6–8 L/min, n = 21); nCPAP (4–6 cm H2O, n = 20)
Manley 2019 Australia RCT 31–34 weeks HHHFNC (6–8 L/min, n = 72); nCPAP (6–8 cm H2O, n = 68)
Mostafa- 2015 Iran RCT 30–34 weeks HHHFNC (6 L/min, n = 42); nCPAP (5–6 cm H2O, n = 43)
Murki 2018 India RCT 28–37 weeks HHHFNC (5–7 L/min, n = 133); nCPAP (5–7 cm H2O, n = 139)
Öktem 2021 Turkey RCT <32 weeks HHHFNC (initial 5 L/min, n = 20); nCPAP (5–6 cm H2O, n = 20)
Roberts 2016 Australia and Norway RCT 28–37 weeks HFNC (6–8 L/min, n = 278); CPAP (6–8 cm H2O, n = 286)
Sharma 2019 India RCT 26–34 weeks HHHFNC (n = 50); nCPAP (n = 50) “detailed parameters” was not provided.
Shin 2017 Korea RCT 30–35weeks HHHFNC (3–7 L/min, n = 42); nCPAP (4–7 cm H2O, n = 43)
Shirvani 2020 Iran RCT <34 weeks HHHFNC (3–7 L/min, n = 30); nCPAP (4–6 cm H2O, n = 30)
Shokouhi 2019 Iran RCT 28–36 weeks HHHFNC (2–8 L/min, n = 30); nCPAP (4–8 cm H2O, n = 30)
Wang 2013 China RCT <32 weeks HHHFNC (2–8 L/min, n = 30); nCPAP (4–8 cm H2O, n = 30)
Wang 2021 China RCT 28–32 weeks HHHFNC (3–8 L/min, n = 62); nCPAP (3–8 cm H2O, n = 63)
Yan 2020 China RCT <37 weeks HHHFNC (2–8 L/min, n = 47); nCPAP (4–8 cm H2O, n = 47)
Yao 2019 China RCT <35 weeks HHHFNC (6–8 L/min, n = 47); nCPAP (5–7 cm H2O, n = 47)
Yoder 2013 US RCT 28–32 weeks HHHFNC (3–8 L/min, n = 75); nCPAP (5–8 cm H2O, n = 75)
Yu 2018 China RCT <36 weeks HHHFNC (1–7 L/min, n = 55); nCPAP (n = 55)
Zhai 2019 China RCT 28–37 weeks HHHFNC (4–6 L/min, n = 38); nCPAP (4–6 cm H2O, n = 35)
Zhang 2017 China RCT <37 weeks HHHFNC (2–8 L/min, n = 44); nCPAP (5–7 cm H2O, n = 45)
Zhang 2019 China RCT <37 weeks HHHFNC (2–8 L/min, n = 40); nCPAP (5–7 cm H2O, n = 40)
Open in a new tab

HFNC, high-flow nasal cannula; HHHFNC, heated humidified high flow nasal cannula; CPAP, continuous positive airway pressure; nCPAP, nasal continuous positive airway pressure.

Risk of bias assessment for included studies

All studies were RCT-design, while the detailed randomization process was not described in 7 studies (24, 40, 42, 46, 48, 50, 54). All the studies reported allocation concealment, but no blinding of participants and personnel or blinding of outcome assessment. Another factor that might compromise the quality of included studies was that few of them (23–25, 30, 38–42, 46–48, 50–57) provided materials to ensure no reporting bias existed (Figures 2, 3, Appendix 2).

Figure 2.

Figure 2

Open in a new tab

Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.

Figure 3.

Figure 3

Open in a new tab

Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.

Primary outcomes

Incidence of treatment failure

There were 22 studies that reported the incidence of respiratory support failure. Meta-analysis based on random effect model (I2 = 62%) showed that there was no significant difference in the incidence of respiratory support failure between HFNC group and CPAP group [RR = 1.17, 95%CI (0.88–1.56)], as shown in Figure 4.

Figure 4.

Figure 4

Open in a new tab

Forest plot of comparison: HFNC vs. CPAP-number-respiratory support failure.

Application of mechanical ventilation

There were 21 studies that reported the application of mechanical ventilation after non-invasive respiratory support. Meta-analysis based on fixed effect model (I2 = 49%) showed that there was no significant difference in the application of respiratory support failure between HFNC group and CPAP group [RR = 1.00, 95%CI (0.84–1.19)], as shown in Figure 5.

Figure 5.

Figure 5

Open in a new tab

Forest plot of comparison: HFNC vs. CPAP-number-mechanical ventilation.

Outcomes of safety

Compared with CPAP group, HFNC resulted lower rate of air leaks [RR = 0.65, 95%CI (0.46–0.92), I2 = 0%], nasal trauma [RR = 0.36, 95%CI (0.29–0.45), I2 = 10%] and abdominal distension [RR = 0.39, 95%CI (0.27–0.58), I2 = 26%], as shown in Figures 6A–C.

Figure 6.

Figure 6

Open in a new tab

(A) forest plot of comparison: HFNC vs. CPAP-number-Air leaks. (B) Forest plot of comparison: HFNC vs. CPAP-number-Nasal trauma. (C) Forest plot of comparison: HFNC vs. CPAP-number-Abdominal distention.

Secondary outcomes

The time of mechanical ventilation initiating in preterm infants was later in HFNC group than in CPAP group [SMD = 0.60, 95%CI (0.21–0.99), I2 = 82%] (Figure 7C). The duration of oxygen therapy in preterm infants in HFNC group was less than those in CPAP group [SMD = −0.35, 95%CI (−0.68 to −0.02), I2 = 91%] (Figure 7F). The time of enteral feeding in preterm infants in HFNC group was earlier than those in CPAP group [SMD = −0.54, 95%CI (−0.95 to −0.13), I2 = 93%] (Figure 7V). Other outcomes did not show any statistically significant differences between the two groups: age of respiratory failure onset (Figure 7A), duration of mechanical ventilation (Figure 7B), duration of respiratory support (Figure 7D)/non-invasive respiratory support (Figure 7E), time of exclusive breastfeeding (Figure 7U), death (Figure 7T), length of hospital stay (Figure 7W), and adverse events of hypercapnia (Figure 7I), apnea (Figure 7J), pulmonary hemorrhage (Figure 7K), pneumonia (Figure 7L), BPD (Figure 7M), sepsis (Figure 7N), NEC (Figure 7O), IVH (Figure 7P), periventricular leukomalacia (Figure 7Q), PDA (Figure 7R), ROP (Figure 7S), and requirement for other treatment (Figures 7G,H).

Figure 7.

Figure 7

Open in a new tab

(A) forest plot of comparison: HFNC vs. CPAP-age-respiratory failure onset. (B) Forest plot of comparison: HFNC vs. CPAP-duration-Mechanical ventilation. (C) Forest plot of comparison: HFNC vs. CPAP-age-Mechanical ventilation initiating. (D) Forest plot of comparison: HFNC vs. CPAP-duration-Respiratory support. (E) Forest plot of comparison: HFNC vs. CPAP-duration-Non-invasive respiratory support. (F) Forest plot of comparison: HFNC vs. CPAP-duration-Oxygen therapy. (G) Forest plot of comparison: HFNC vs. CPAP-number-Surfactant. (H) Forest plot of comparison: HFNC vs. CPAP-number-Surfactant with multiple doses. (I) Forest plot of comparison: HFNC vs. CPAP-number-Hypercapnia. (J) Forest plot of comparison: HFNC vs. CPAP-number-Apnea. (K) Forest plot of comparison: HFNC vs. CPAP-number-Pulmonary hemorrhage. (L) Forest plot of comparison: HFNC vs. CPAP-number-Pneumonia. (M) Forest plot of comparison: HFNC vs. CPAP-number-Bronchopulmonary dysplasia. (N) Forest plot of comparison: HFNC vs. CPAP-number-Sepsis. (O) Forest plot of comparison: HFNC vs. CPAP-number-Necrotizing enterocolitis. (P) Forest plot of comparison: HFNC vs. CPAP-number-Intraventricular hemorrhage. (Q) Forest plot of comparison: HFNC vs. CPAP-number-Periventricular leukomalacia. (R) Forest plot of comparison: HFNC vs. CPAP-number-Patent ductus arteriosus. (S) Forest plot of comparison: HFNC vs. CPAP-number-Retinopathy of prematurity. (T) Forest plot of comparison: HFNC vs. CPAP-number-Death. (U) Forest plot of comparison: HFNC vs. CPAP-number-Exclusive breastfeeding. (V) Forest plot of comparison: HFNC vs. CPAP-age-Enteral feeding. (W) Forest plot of comparison: HFNC vs. CPAP-length-Hospital stay.

Sensitivity analysis

After removing the studies that increase heterogeneity of this meta-analysis, there were significant differences in the duration of non-invasive respiratory support [SMD = 0.05, 95%CI (−0.08 to 0.18), I2 = 0%], time of enteral feeding [SMD = −0.05, 95%CI (−0.15 to 0.05), I2 = 0%], duration of mechanical ventilation [SMD = −0.22, 95%CI (−0.59 to 0.14), I2 = 51%], duration of oxygen therapy [SMD = −0.03, 95%CI (−0.13 to 0.17), I2 = 17%), and incidence of respiratory support failure [RR = 1.06, 95%CI (0.85–1.32), I2 = 39%) (Figures 8A–E).

Figure 8.

Figure 8

Open in a new tab

(A) Forest plot of comparison: HFNC vs. CPAP-duration-Non-invasive respiratory support (after removing “Zhang 2017” and “Zhang 2019”). (B) Forest plot of comparison: HFNC vs. CPAP-age-Enteral feeding (after removing “Zhang 2017” and “Zhang 2019”). (C) Forest plot of comparison: HFNC vs. CPAP-duration-Mechanical ventilation (after removing “Zhang 2017”). (D) Forest plot of comparison: HFNC vs. CPAP-duration-Oxygen therapy (after removing “Zhang 2017” and “Zhang 2019”). (E) Forest plot of comparison: HFNC vs. CPAP-number-Respiratory support failure (after removing “Armanian 2019”, “Manley 2019”, “Murki 2018”, “Roberts 2016”, “Shin 2017”, and “Zhang 2017”).

In five studies (30, 31, 37, 43, 45), alternative non-invasive respiratory support was used as a remedy for treatment failure (Table 2). Since the data of mechanical ventilation for preterm infants were not provided in “Manley 2019” (43), we evaluated the application of mechanical ventilation in the other four studies, and found that alternative non-invasive respiratory support after initial treatment failure resulted in no difference in the application of mechanical ventilation between HFNC group and CPAP group [RR = 0.99, 95%CI (0.52–1.88), I2 = 57%] (Figure 9).

Table 2.

Alternative non-invasive respiratory support was used as a remedy for treatment failure.

Author Year Respiratory support when HFNC/CPAP fails
Armanian 2019 From HFNC/CPAP to NIMV, NCPAP, or MV.
Manley 2019 From HFNC to CPAP/MV and from CPAP to MV.
Murki 2018 From HFNC to CPAP/MV and from CPAP to MV.
Roberts 2016 From HFNC to CPAP/MV and from CPAP to MV.
Shin 2017 From HFNC to CPAP/MV and from CPAP to Bilevel CPAP/MV.
Open in a new tab

HFNC, high-flow nasal cannula; CPAP, continuous positive airway pressure; NCPAP, nasal continuous positive airway pressure; NIMV, nasal intermittent mandatory ventilation; MV, mechanical ventilation.

Figure 9.

Figure 9

Open in a new tab

Forest plot of comparison: HFNC vs. CPAP-number-Mechanical ventilation in the studies using alternative non-invasive respiratory support as a remedy for treatment failure.

Discussion

Among the two systematic reviews (32, 34) that were published previously to compare HFNC and CPAP for preterm respiratory distress, one (32) suggested that the both had similar treatment failure rates, while the other (34) proposed that the former resulted in a higher treatment failure rate. In comparison, our study has the following advantages. First, the cut-off years for the included studies were updated, and the search for articles published in Chinese was more comprehensive. Second, this study analyzed multiple respiratory indicators which the previous studies did not included, like duration of mechanical ventilation/non-invasive respiratory support/oxygen therapy, age to use mechanical ventilation, etc. Third, we evaluated the potential of CPAP to be a remedy to avoid intubation when HFNC failed.

In the sensitivity analysis, removing “Zhang 2017” (56) and “Zhang 2019” (57) eliminated the heterogeneity among studies, and the results of the duration of oxygen therapy, duration of mechanical ventilation, duration of non-invasive respiratory support, and time of enteral feeding were reversed, which indicated that there might be bias in these two studies, such as reporting bias due to the lack of protocols, and other undetected bias. In “Armanian 2019” (37), “Manley 2019” (43), “Murki 2018” (45), “Roberts 2016” (31) and “Shin 2017” (30), preterm infants with treatment failure were not all intubated and mechanically ventilated. Some were replaced with non-invasive respiratory support. The analysis for the incidence of mechanical ventilation showed no difference, indicating that there might be no difference in the use of non-invasive respiratory support approaches between the two groups, and that it might be because the included studies did not apply an unified applicable standard for the use of non-invasive respiratory support. For the incidence of respiratory support failure, I² decreased from 62% to 39% after removing “Armanian 2019” (37), “Manley 2019” (43), “Murki 2018” (45), “Roberts 2016” (31), “Shin 2017” (30), and “Zhang 2017” (56).

In our meta-analysis, incidence of respiratory support failure and mechanical ventilation were adopted to evaluate the efficacy of HFNC and CPAP as primary respiratory support for preterm infants and the results showed no statistical difference. This is consistent with the results of previous studies. Several RCTs and meta-analysis found that HFNC had similar efficacy and safety with CPAP in the initial treatment of neonates with NRDS. There was no significant difference between HFNC and CPAP in the intubation rate and other serious complications (23–29). However, a growing number of studies in recent years have produced conflicting results. An RCT comparing HFNC and CPAP as the initial treatment for preterm infants with NRDS found that although HFNC had no significant difference in complications compared with CPAP, it had a higher failure rate (30). Several RCTs and systematic reviews found that HFNC had a significantly higher therapeutic failure rate than CPAP when used as early respiratory support for neonates with NRDS (31, 33, 34), which indicated that HFNC might be not suitable for the primary respiratory support for preterm infants, and such conclusion might be related to the fact that there was a gap between the nasal prong and the nasal cavity during HFNC treatment, thus the airway pressure could not be well controlled. Both the HFNC and CPAP could provide positive pressure to help delating the airway at an oxygen flow rate over 2l/min, while the pressure provided by HFNC could be affected by the size of nasal prong, gas flow, trachea diameter, air leakage, and the body weight of the newborns, making it difficult to precisely evaluate the pressure generated by HFNC (58).

This study showed that HFNC had a lower risk for air leaks, nasal trauma and abdominal distension than CPAP, suggesting a better safety in HFNC. The lower risk for nasal trauma in the use of HFNC might be related to that the nasal prong does not close the nasal cavity completely, which prevents compression of the skin around the nose, and heated and humidified air flow can reduce the incidence of nasal mucosal injury and bleeding so that to increase the comfort of infants (20). Studies (59, 60) showed that HFNC produced lower positive airway pressure than CPAP. An animal experiment found that HFNC produced airway pressure of approximately 3–3.5 cm H2O at a flow rate of 6 L/min (60). The above reasons could explain the lower incidence of air leaks and abdominal distension in HFNC compared with CPAP.

Analyses for secondary outcomes showed that the time of mechanical ventilation initiating for preterm infants was later in HFNC group than in CPAP group, which might be associated with the operating mechanism of HFNC. Compared with CPAP, the gas flow rate of HFNC can produce a positive end-expiratory pressure to promote lung expansion and improve alveolar distension (15–18). Also, high-flow gas can flush the anatomic dead cavity in nasopharynx, contributing to the removal of carbon dioxide and the improvement of gas exchange (14, 19). The air flow provided by HFNC exceeds the patient's maximum inspiratory flow, which can minimize the inspiratory resistance of the upper respiratory tract and reduce the work of breath (19). The lower incidence of abdominal distension in HFNC group might be related to earlier attainment of enteral feeding.

Two of the included studies analyzed ultra-premature infants under 28 weeks of gestation. In “Demirel 2019” (25), no significant difference of efficacy and safety was found between HFNC group and CPAP group for ultra-premature infants. In “Öktem 2021” (46), the intubation rate was higher in CPAP group than in HFNC group for the same population (60% vs. 15%, p = 0.02). “Sharma 2019” (47) included infants with the gestational age of 26–34 weeks, but did not provide the detailed characteristics of participants. The other included studies did not specifically report whether there were newborns with the gestational age of less than 28 weeks.

However, there are limitations in our meta-analysis. First, there were differences in the baseline characteristics of the included neonates, such as gestational age, birth weight, concomitant NRDS, the severity of NRDS, flow rate of HFNC, pressure of CPAP, which might lead to heterogeneity among studies. Second, due to the lack of specific data on individuals, subgroup analysis based on gestational age or birth weight could not be performed. Third, the included studies did not report all the outcomes in our meta-analysis, which might affect the robustness of the results. Forth, we have expressed there is 25% selection bias and 75% reporting bias. Among them, blinding of participants and personnel or blinding of outcome assessment are unavoidable because the subjects of the study are infants. Furthermore, among the RCTs included, studies from China accounted for the largest proportion, so the applicability of the conclusions in other regions needs to be further verified.

Conclusion

Compared with CPAP, the use of HFNC for preterm infants might be more effective in reducing the use of mechanical ventilation and oxygen therapy, and has lower risks for air leaks, nasal trauma and abdominal distension. Using CPAP as a remedy for the treatment failure of HFNC could not avoid intubation. For premature infants with the gestational age less than 28 weeks, the use of HFNC as the primary respiratory support still needs to be further elucidated.

Funding

This work was supported by the National Natural Science 2Foundation of China (General Program, Grant No. 82171710).

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author contributions

KL wrote the main manuscript and fully participated in all analyses. JT contributed to the study concept and design. YH and TX participated in literature search, data extraction, and quality assessment. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.980024/full#supplementary-material.

Datasheet1.zip (816.7KB, zip)

References

  • 1.Motojima Y, Ito M, Oka S, Uchiyama A, Tamura M, Namba F. Use of high-flow nasal cannula in neonates: nationwide survey in Japan. Pediatr Int. (2016) 58(4):308–10. 10.1111/ped.12903 [DOI] [PubMed] [Google Scholar]
  • 2.Manley BJ. Nasal high-flow therapy for preterm infants: review of neonatal trial data. Clin Perinatol. (2016) 43(4):673–91. 10.1016/j.clp.2016.07.005 [DOI] [PubMed] [Google Scholar]
  • 3.Alallah J. Early CPAP versus surfactant in extremely preterm infants. J Clin Neonatol. (2012) 1(1):12–3. 10.4103/2249-4847.92233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lissauer T, Duke T, Mellor K, Molyneux L. Nasal CPAP for neonatal respiratory support in low and middle-income countries. Arch Dis Child Fetal Neonatal Ed. (2017) 102(3):F194–F6. 10.1136/archdischild-2016-311653 [DOI] [PubMed] [Google Scholar]
  • 5.Jatana KR, Oplatek A, Stein M, Phillips G, Kang DR, Elmaraghy CA. Effects of nasal continuous positive airway pressure and cannula use in the neonatal intensive care unit setting. Arch Otolaryngol Head Neck Surg. (2010) 136(3):287–91. 10.1001/archoto.2010.15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Li SN, Li L, Li CL, Zhou SP, Lu WC. The safety and effectiveness of heated humidified high-flow nasal cannula as an initial ventilation method in the treatment of neonatal respiratory distress syndrome: a protocol for systematic review and meta-analysis. Medicine. (2020) 99(46):e23243. 10.1097/MD.0000000000023243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rodriguez Losada O, Montaner Ramón A, Gregoraci Fernández A, Flores España V, Gros Turpin A, Comuñas Gómez JJ, et al. Use of high flow nasal cannula in spanish neonatal units. Anales de Pediatria. (2021) 96:319–25. 10.1016/j.anpedi.2021.02.012 [DOI] [PubMed] [Google Scholar]
  • 8.Hosheh O, Edwards CT, Ramnarayan P. A nationwide survey on the use of heated humidified high flow oxygen therapy on the paediatric wards in the UK: current practice and research priorities. BMC Pediatr. (2020) 20(1):109. 10.1186/s12887-020-1998-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Petrillo F, Gizzi C, Maffei G, Matassa PG, Ventura ML, Ricci C, et al. Neonatal respiratory support strategies for the management of extremely low gestational age infants: an Italian survey. Ital J Pediatr. (2019) 45(1):44. 10.1186/s13052-019-0639-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Eklund WM, Scott PA. High-Flow nasal cannula practice patterns reported by neonatologists and neonatal nurse practitioners in the United States. Adv Neonatal Care. (2018) 18(5):400–12. 10.1097/ANC.0000000000000536 [DOI] [PubMed] [Google Scholar]
  • 11.Schmid F, Olbertz DM, Ballmann M. The use of high-flow nasal cannula (HFNC) as respiratory support in neonatal and pediatric intensive care units in Germany - A nationwide survey. Respir Med. (2017) 131:210–4. 10.1016/j.rmed.2017.08.027 [DOI] [PubMed] [Google Scholar]
  • 12.Mukerji A, Shah PS, Shivananda S, Yee W, Read B, Minski J, et al. Survey of noninvasive respiratory support practices in Canadian neonatal intensive care units. Acta Paediatrica. (2017) 106(3):387–93. 10.1111/apa.13644 [DOI] [PubMed] [Google Scholar]
  • 13.Roberts CT, Owen LS, Manley BJ, Davis PG. High-flow support in very preterm infants in Australia and New Zealand. Arch Dis Child Fetal Neonatal Ed. (2016) 101(5):F401–3. 10.1136/archdischild-2015-309328 [DOI] [PubMed] [Google Scholar]
  • 14.Hodgson KA, Davis PG, Owen LS. Nasal high flow therapy for neonates: current evidence and future directions. J Paediatr Child Health. (2019) 55(3):285–90. 10.1111/jpc.14374 [DOI] [PubMed] [Google Scholar]
  • 15.Spence KL, Murphy D, Kilian C, McGonigle R, Kilani RA. High-flow nasal cannula as a device to provide continuous positive airway pressure in infants. J Perinatol. (2007) 27(12):772–5. 10.1038/sj.jp.7211828 [DOI] [PubMed] [Google Scholar]
  • 16.Yengkhom R, Suryawanshi P, Gupta B, Deshpande S. Heated humidified high-flow nasal cannula vs. Nasal continuous positive airway pressure for post-extubation respiratory support in preterm infants: a randomized controlled trial. J Trop Pediatr. (2021 Jan 29) 67(1):fmaa082. 10.1093/tropej/fmaa082 [DOI] [PubMed] [Google Scholar]
  • 17.Hasan RA, Habib RH. Effects of flow rate and airleak at the nares and mouth opening on positive distending pressure delivery using commercially available high-flow nasal cannula systems: a lung model study. Pediatr Crit Care Med. (2011) 12(1):e29–33. 10.1097/PCC.0b013e3181d9076d [DOI] [PubMed] [Google Scholar]
  • 18.Kubicka ZJ, Limauro J, Darnall RA. Heated, humidified high-flow nasal cannula therapy: yet another way to deliver continuous positive airway pressure? Pediatrics. (2008) 121(1):82–8. 10.1542/peds.2007-0957 [DOI] [PubMed] [Google Scholar]
  • 19.Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med. (2009) 103(10):1400–5. 10.1016/j.rmed.2009.04.007 [DOI] [PubMed] [Google Scholar]
  • 20.Chao KY, Chen YL, Tsai LY, Chien YH, Mu SC. The role of heated humidified high-flow nasal cannula as noninvasive respiratory support in neonates. Pediatr Neonatol. (2017) 58(4):295–302. 10.1016/j.pedneo.2016.08.007 [DOI] [PubMed] [Google Scholar]
  • 21.Pediatrics ECoCJo. Neonatal mechanical ventilation routine. Chin J Pediatr. (2015) 53(5):4. 10.3760/cma.j.issn.0578-1310.2015.05.003 [DOI] [Google Scholar]
  • 22.Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, et al. European Consensus guidelines on the management of respiratory distress syndrome - 2016 update. Neonatology. (2017) 111(2):107–25. 10.1159/000448985 [DOI] [PubMed] [Google Scholar]
  • 23.Lavizzari A, Colnaghi M, Ciuffini F, Veneroni C, Musumeci S, Cortinovis I, et al. Heated, humidified high-flow nasal cannula vs nasal continuous positive airway pressure for respiratory distress syndrome of prematurity: a randomized clinical noninferiority trial. JAMA Pediatr. (2016). 10.1001/jamapediatrics.2016.1243. [Online ahead of print] [DOI] [PubMed] [Google Scholar]
  • 24.Chen J, Gao WW, Xu F, Du LL, Zhang T, Ling X, et al. Comparison of clinical efficacy of heated humidified high flow nasal cannula versus nasal continuous positive airway pressure in treatment of respiratory distress syndrome in very low birth weight infants. Zhongguo Dang Dai Er Ke Za Zhi. (2015) 17(8):847–51. 10.7499/j.issn.1008-8830.2015.08.017 [DOI] [PubMed] [Google Scholar]
  • 25.Demirel G, Vatansever B, Tastekin A. High flow nasal cannula versus nasal continuous positive airway pressure for primary respiratory support in preterm infants: a prospective randomized study. Am J Perinatol. (2021) 38(3):237–41. 10.1055/s-0039-1696673 [DOI] [PubMed] [Google Scholar]
  • 26.Kotecha SJ, Adappa R, Gupta N, Watkins WJ, Kotecha S, Chakraborty M. Safety and efficacy of high-flow nasal cannula therapy in preterm infants: a meta-analysis. Pediatrics. (2015) 136(3):542–53. 10.1542/peds.2015-0738 [DOI] [PubMed] [Google Scholar]
  • 27.Wilkinson D, Andersen C, O'Donnell CP, De Paoli AG, Manley BJ. High flow nasal cannula for respiratory support in preterm infants. Cochrane Database Syst Rev. (2016) 2:Cd006405. 10.1002/14651858.CD006405.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yoder BA, Stoddard RA, Li M, King J, Dirnberger DR, Abbasi S. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. Pediatrics. (2013) 131(5):e1482–90. 10.1542/peds.2012-2742 [DOI] [PubMed] [Google Scholar]
  • 29.Fleeman N, Dundar Y, Shah PS, Shaw BN. Heated humidified high-flow nasal cannula for preterm infants: an updated systematic review and meta-analysis. Int J Technol Assess Health Care. (2019) 35(4):298–306. 10.1017/S0266462319000424 [DOI] [PubMed] [Google Scholar]
  • 30.Shin J, Park K, Lee EH, Choi BM. Humidified high flow nasal cannula versus nasal continuous positive airway pressure as an initial respiratory support in preterm infants with respiratory distress: a randomized, controlled non-inferiority trial. J Korean Med Sci. (2017) 32(4):650–5. 10.3346/jkms.2017.32.4.650 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Roberts CT, Owen LS, Manley BJ, Frøisland DH, Donath SM, Dalziel KM, et al. Nasal high-flow therapy for primary respiratory support in preterm infants. N Engl J Med. (2016) 375(12):1142–51. 10.1056/NEJMoa1603694 [DOI] [PubMed] [Google Scholar]
  • 32.Hong H, Li XX, Li J, Zhang ZQ. High-flow nasal cannula versus nasal continuous positive airway pressure for respiratory support in preterm infants: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med. (2021) 34(2):259–66. 10.1080/14767058.2019.1606193 [DOI] [PubMed] [Google Scholar]
  • 33.Conte F, Orfeo L, Gizzi C, Massenzi L, Fasola S. Rapid systematic review shows that using a high-flow nasal cannula is inferior to nasal continuous positive airway pressure as first-line support in preterm neonates. Acta Paediatrica. (2018) 107(10):1684–96. 10.1111/apa.14396 [DOI] [PubMed] [Google Scholar]
  • 34.Bruet S, Butin M, Dutheil F. Systematic review of high-flow nasal cannula versus continuous positive airway pressure for primary support in preterm infants. Arch Dis Child Fetal Neonatal Ed. (2022) 107(1):56–9. 10.1136/archdischild-2020-321094 [DOI] [PubMed] [Google Scholar]
  • 35.Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. (2015) 162(11):777–84. 10.7326/M14-2385 [DOI] [PubMed] [Google Scholar]
  • 36.Keren L, Jun T. High-flow nasal cannula versus continuous positive airway pressure for primary respiratory support in preterm infants: a systematic review and meta-analysis. [Google Scholar]
  • 37.Armanian AM, Iranpour R, Parvaneh M, Salehimehr N, Feizi A, Hajirezaei M. Heated humidified high flow nasal cannula (HHHFNC) is not an effective method for initial treatment of respiratory distress syndrome (RDS) versus nasal intermittent mandatory ventilation (NIMV) and nasal continuous positive airway pressure (NCPAP). J Res Med Sci. (2019) 24:73. 10.4103/jrms.JRMS_2_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ciuffini F, Pietrasanta C, Lavizzari A, Musumeci S, Gualdi C, Sortino S, et al. Comparison between two different modes of non-invasive ventilatory support in preterm newborn infants with respiratory distress syndrome mild to moderate: preliminary data. Pediatr Med Chir. (2014) 36(4):88. 10.4081/pmc.2014.88 [DOI] [PubMed] [Google Scholar]
  • 39.Farhat AS, Mohammadzadeh A, Mamuri GA, Saeidi R, Orizadeh SN. Comparison of nasal non-invasive ventilation methods in preterm neonates with respiratory distress syndrome. Iran J Neonatol. (2018) 9(4):53–60. 10.22038/ijn.2018.24544.1313 [DOI] [Google Scholar]
  • 40.Lin F, Yan L, Danhua M, Hongjuan B, Lipin Y, Jin X, et al. Clinical trial on the effectiveness and safety of high flow nasal cannula oxygen therapy in preterm infants. Chinese J Clin Nutr. (2016) 3(26):2. [Google Scholar]
  • 41.Kadivar M, Mosayebi Z, Razi N, Nariman S, Sangsari R. High flow nasal cannulae versus nasal continuous positive airway pressure in neonates with respiratory distress syndrome managed with INSURE method: a randomized clinical trial. Iran J Med Sci. (2016) 41(6):494. PMID: 27853329 [PMC free article] [PubMed] [Google Scholar]
  • 42.Li Wenying QA, Xiaojiao W, Yuanyuan W. Clinical observation on RDS treated with three kinds of auxiliary ventilation combined with pulmonary surfactant in low weight premature infants. J Pediatr Pharmacol. (2014) 07(20):4. 10.13407/j.cnki.jpp.1672-108X.2014.07.007 [DOI] [Google Scholar]
  • 43.Manley BJ, Arnolda GRB, Wright IMR, Owen LS, Foster JP, Huang L, et al. Nasal high-flow therapy for newborn infants in special care nurseries. N Engl J Med. (2019) 380(21):2031–40. 10.1056/NEJMoa1812077 [DOI] [PubMed] [Google Scholar]
  • 44.Mostafa-Gharehbaghi M, Mojabi H. Comparing the effectiveness of nasal continuous positive airway pressure (NCPAP) and high flow nasal cannula (HFNC) in prevention of post extubation assisted ventilation. Zahedan J Res Med Sci. (2015) 17(6):e984. 10.17795/zjrms984 [DOI] [Google Scholar]
  • 45.Murki S, Singh J, Khant C, Kumar Dash S, Oleti TP, Joy P, et al. High-Flow nasal cannula versus nasal continuous positive airway pressure for primary respiratory support in preterm infants with respiratory distress: a randomized controlled trial. Neonatology. (2018) 113(3):235–41. 10.1159/000484400 [DOI] [PubMed] [Google Scholar]
  • 46.Öktem A, Yiğit Ş, Çelik HT, Yurdakök M. Comparison of four different non-invasive respiratory support techniques as primary respiratory support in preterm infants. Turk J Pediatr. (2021) 63(1):23–30. 10.24953/turkjped.2021.01.003 [DOI] [PubMed] [Google Scholar]
  • 47.Sharma PK, Poonia AK, Bansal RK. Comparison of efficacy of nasal continuous positive airway pressure and heated humidified high-flow nasal cannula as a primary mode of respiratory support in preterm infants. J Clin Neonatol. (2019) 8(2):102. 10.4103/jcn.JCN_116_18 [DOI] [Google Scholar]
  • 48.Shirvani TE, Nayeri FS, Shariat M, Nafs NN, Mirjalili MR, Hosseini SN, et al. Continuous positive airway pressure or humidified high flow nasal cannula for respiratory distress syndrome: a randomized control trial among premature neonates. Iran J Neonatol. (2020) 11(4):50–6. 10.22038/ijn.2020.46421.1783 [DOI] [Google Scholar]
  • 49.Shokouhi M, Basiri B, Sabzehei MK, Mandiankhoo M, Pirdehghan A. Efficacy and complications of humidified high-flow nasal cannula versus nasal continuous positive airway pressure in neonates with respiratory distress syndrome after surfactant therapy. Iran Red Crescent Med J. (2019) 21(2):e83615. 10.5812/ircmj.83615 [DOI] [Google Scholar]
  • 50.Yue W, Weiwei W, Yunbin C, Xiuzhen Y, Yong Z, Fang L. Early HHFNC versus nCPAP in very low birth weight preterm infants. Chin J Women Child Health. (2013) 4(4):13–14. 10.19757/j.cnki.issn1674-7763.2013.z1.005 [DOI] [Google Scholar]
  • 51.Jing W, Xiaoli W, Junli L, Yan W, Guo Y, Baohai S. Effect of heated humidified high flow nasal cannula in treatment for neonatal respiratory distress syndrome. Chin Med Eng. (2021) 3(29):6. 10.19338/j.issn.1672-2019.2021.03.019 [DOI] [Google Scholar]
  • 52.YAN Hui-yu Y-h. Value analysis of warming and humidifying high-flow nasal catheter ventilation in the treatment of respiratory distress syndrome in premature infants. World J Complex Med. (2020) 6(6):3. 10.11966/j.issn.2095-994X.2020.06.06.32 [DOI] [Google Scholar]
  • 53.YAO Fan XB, Shisi LIN, Qin LI. Comparison of clinical curative effects of nasal continuous positive airway pressure ventilation and humidified high flow nasal cannula in treatment of neonatal respiratory distress syndrome. Chin Med Pharm. (2019) 22(9):4. 10.3969/j.issn.2095-0616.2019.22.023 [DOI] [Google Scholar]
  • 54.Xiao-ping Y. Clinical analysis of different auxiliary ventilation methods to prevent extubation failure in very low birth weight premature infants. Smart Healthcare. (2018) 4(14):3. 10.19335/j.cnki.2096-1219.2018.14.017 [DOI] [Google Scholar]
  • 55.Zhai Jingfang WJ, Bao J, Xiao L, Yanbo W, Guangling Z, Xiaoyu S, et al. Comparison of heated humidified high flow nasal cannula and nasal continuous positive airway pressure in initial respiratory support of mild neonatal respiratory distress syndrome. Chin J Obstet Gynecol Pediatr. (2019) 6(15):7. 10.3877/cma.j.issn.1673-5250.2019.06.005 [DOI] [Google Scholar]
  • 56.Ji-hua YJ-m ZHANG, Yu-hong DING. Study on the efficacy of application of two kinds of auxiliary ventilation in treatment of respiratory distress syndrome in neonates with very low birth weight. J Clin Exp Med. (2017) 16(23):4. 10.3969/j.issn.1671-4695.2017.23.028 [DOI] [Google Scholar]
  • 57.Zhihua Z. Application of two kinds of non-invasive positive pressure ventilation in the treatment of neonatal respiratory distress syndrome. Med Inno of Chin. (2019) 16(20):4. 10.3969/j.issn.1674-4985.2019.20.031 [DOI] [Google Scholar]
  • 58.Jeon GW. Respiratory support with heated humidified high flow nasal cannula in preterm infants. Korean J Pediatr. (2016) 59(10):389–94. 10.3345/kjp.2016.59.10.389 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Lampland AL, Plumm B, Meyers PA, Worwa CT, Mammel MC. Observational study of humidified high-flow nasal cannula compared with nasal continuous positive airway pressure. J Pediatr. (2009) 154(2):177–82. 10.1016/j.jpeds.2008.07.021 [DOI] [PubMed] [Google Scholar]
  • 60.Frizzola M, Miller TL, Rodriguez ME, Zhu Y, Rojas J, Hesek A, et al. High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. Pediatr Pulmonol. (2011) 46(1):67–74. 10.1002/ppul.21326 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Datasheet1.zip (816.7KB, zip)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Articles from Frontiers in Pediatrics are provided here courtesy of Frontiers Media SA

RESOURCES